Journal of Clinical Oncology, Vol 11, 255-261, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age

JF Abrahamsen, A Andersen, E Hannisdal, O Nome, AF Abrahamsen, S Kvaloy and H Host
Norwegian Radium Hospital, Oslo.

PURPOSE: In the period 1968 through 1988, The Norwegian Radium Hospital (NRH) treated an unselected population of 1,152 patients with Hodgkin's disease (HD) that comprised more older patients (mean age, 43 years) than most other institutions. We considered it important to evaluate these patients for development of second cancers (SCs). PATIENTS AND METHODS: The Norwegian Cancer Registry identified previously untreated patients with HD treated at NRH who had developed a SC more than 1 year after diagnosis of HD. The relative risk ratio (RR) (observed/expected cases) and the cumulative risk were calculated. RESULTS: Sixty-eight patients had developed a SC, including nine acute nonlymphocytic leukemias (ANLLs), eight non-Hodgkin's lymphomas (NHLs), and 51 solid tumors, including 11 lung cancers. The RR of SC and leukemia was 1.86 (95% confidence interval [CI], 1.4 to 2.4) and 24.3 (95% CI, 11.1 to 46.2), respectively. The RR of SC was highest in younger patients (< 41 years, RR = 3.8). No significant association between splenectomy and development of ANLL was found. The influence of treatment and follow-up time on the development of SC agrees with data from other large cancer institutions. CONCLUSION: (1) The low RR of developing a SC in this study is probably due to the number of older patients included, who have a lower RR of developing a SC due to less aggressive treatment, shorter follow-up time, and higher incidence of cancer in the expected background population. (2) The low RR and cumulative risk of developing ANLL may be due to the limited use of extensive chemotherapy (CT) in our hospital in the earlier years.

This article has been cited by other articles:

				V. Pavone, U. Ricardi, S. Luminari, P. Gobbi, M. Federico, L. Baldini, E. Iannitto, G. Ucci, L. Marcheselli, L. Orsucci, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study Ann. Onc., April 1, 2008; 19(4): 763 - 768. [Abstract] [Full Text] [PDF]

				J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]

				D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002. [Abstract] [Full Text] [PDF]

				M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients Blood, February 15, 2004; 103(4): 1222 - 1228. [Abstract] [Full Text] [PDF]

				A. Foss Abrahamsen, A. Andersen, O. Nome, A. B. Jacobsen, H. Holte, J. Foss Abrahamsen, and S. Kvaloy Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time Ann. Onc., November 1, 2002; 13(11): 1786 - 1791. [Abstract] [Full Text] [PDF]

				G. M. Dores, C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, F. E. van Leeuwen, E. J. Holowaty, et al. Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years J. Clin. Oncol., August 15, 2002; 20(16): 3484 - 3494. [Abstract] [Full Text] [PDF]

				C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma Ann. Onc., March 1, 2002; 13(3): 450 - 459. [Abstract] [Full Text] [PDF]

				U. Rueffer, A. Josting, J. Franklin, M. May, M. Sieber, K. Breuer, A. Engert, and V. Diehl Non-Hodgkin's Lymphoma After Primary Hodgkin's Disease in the German Hodgkin's Lymphoma Study Group: Incidence, Treatment, and Prognosis J. Clin. Oncol., April 1, 2001; 19(7): 2026 - 2032. [Abstract] [Full Text] [PDF]

				A. J. Swerdlow, M. J. Schoemaker, R. Allerton, A. Horwich, J. A. Barber, D. Cunningham, T. A. Lister, A. Z.S. Rohatiner, G. Vaughan Hudson, M. V. Williams, et al. Lung Cancer After Hodgkin's Disease: A Nested Case-Control Study of the Relation to Treatment J. Clin. Oncol., March 15, 2001; 19(6): 1610 - 1618. [Abstract] [Full Text] [PDF]

				C. Metayer, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, T. Joensuu, F. E. van Leeuwen, M. B. van't Veer, R. E. Curtis, et al. Second Cancers Among Long-Term Survivors of Hodgkin's Disease Diagnosed in Childhood and Adolescence J. Clin. Oncol., June 12, 2000; 18(12): 2435 - 2443. [Abstract] [Full Text] [PDF]

				I. N. M. Micallef, D. M. Lillington, J. Apostolidis, J. A. L. Amess, M. Neat, J. Matthews, T. Clark, J. M. Foran, A. Salam, T. A. Lister, et al. Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies J. Clin. Oncol., March 1, 2000; 18(5): 947 - 947. [Abstract] [Full Text] [PDF]

				D. C. Linch, R. G. Gosden, T. Tulandi, S.-L. Tan, and S. L. Hancock Hodgkin's Lymphoma: Choice of Therapy and Late Complications Hematology, January 1, 2000; 2000(1): 205 - 221. [Abstract] [Full Text] [PDF]

				J. H. Loge, A. F. Abrahamsen, O. Ekeberg, and S. Kaasa Hodgkin's Disease Survivors More Fatigued Than the General Population J. Clin. Oncol., January 1, 1999; 17(1): 253 - 253. [Abstract] [Full Text] [PDF]

				T. P. Miller, S. Dahlberg, J. R. Cassady, D. J. Adelstein, C. M. Spier, T. M. Grogan, M. LeBlanc, S. Carlin, E. Chase, and R. I. Fisher Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma N. Engl. J. Med., July 2, 1998; 339(1): 21 - 26. [Abstract] [Full Text] [PDF]

				P. G. Gobbi, C. Pieresca, M. L. Ghirardelli, N. DiRenzo, M. Federico, F. Merli, E. Iannitto, V. Pitini, G. Grignani, A. Donelli, et al. Long-Term Results From MOPPEBVCAD Chemotherapy With Optional Limited Radiotherapy in Advanced Hodgkin's Disease Blood, April 15, 1998; 91(8): 2704 - 2712. [Abstract] [Full Text] [PDF]

				G. Nadali, L. Tavecchia, E. Zanolin, V. Bonfante, S. Viviani, E. Camerini, P. Musto, N. Di Renzo, M. Carotenuto, M. Chilosi, et al. Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin's Disease at High Risk of Unfavorable Outcome Blood, April 15, 1998; 91(8): 3011 - 3016. [Abstract] [Full Text] [PDF]

				J. G. Krikorian and D. E. Palmer-Toy Case 38-1997- Inflammation of the Ears, Anemia, and Fever 21 Years after Treatment for Hodgkin's Disease N. Engl. J. Med., December 11, 1997; 337(24): 1753 - 1760. [Full Text] [PDF]

				S. Bhatia, L. L. Robison, O. Oberlin, M. Greenberg, G. Bunin, F. Fossati-Bellani, and A. T. Meadows Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease N. Engl. J. Med., March 21, 1996; 334(12): 745 - 751. [Abstract] [Full Text] [PDF]

				P. S. Multani and M. L. Grossbard Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary? Oncologist, February 1, 1996; 1(1): 41 - 55. [Abstract] [Full Text] [PDF]

				M. L. Grossbard and N. L. Harris Case 10-1994- A 37-Year-Old Woman with Thrombocytopenia and a Paragastric Mass after Treatment for Hodgkin's Disease N. Engl. J. Med., March 10, 1994; 330(10): 698 - 704. [Full Text]